Third gasotransmitter garners interest
This article was originally published in Scrip
Twenty years ago, three US researchers were awarded the Nobel Prize in Physiology or Medicine for their discoveries concerning nitric oxide (NO) as a signalling molecule in the cardiovascular system. Until then, NO had been looked upon mainly as an air pollutant, and its identification as a signalling molecule was particularly surprising as chemically it was totally unlike any other signalling molecule known at the time. The researchers discovered that NO was rapidly converted to nitrite and nitrate within the body: suddenly, the use of nitrates to treat conditions such as angina made a lot more sense.
You may also be interested in...
The health care industry has come a long way in the past 35 years, although in some areas very little has changed. Recently retired In Vivo editor Peter Charlish has seen most of the major developments, and in his final feature, he looks back at some of the big stories in a reporting career that began in the early 1980s.
Less invasive transcatheter techniques will increasingly displace older, riskier open-heart procedures in the treatment of heart valve disease, according to a new Meddevicetracker report. By 2021, transcatheter systems will account for 76% of the global market for heart valve disease treatment products, with the US retaining its current dominant position in this sector.
The market for minimally invasive weight loss devices will reach more than $290 million by 2021, according to a new report from Informa’s Meddevicetracker. Issues relating to laparoscopic adjustable gastric banding systems will result in a greater emphasis being placed on intragastric balloons, which will grow at twice the segment average.